Company Profile
Kyverna Therapeutics Stock Price, News & Analysis
- Ticker:
- KYTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.75 USD (+1.44%)
Close
Last updated: August 6, 2026
480M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KYTX closed up 1.44% at $7.75. No new same-company headline was identified in the current news window.
Company overview
Autoimmune CAR T Company
Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.
Miv-cel
Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration.
Stiff Person Syndrome
The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
Broader Autoimmune Development
Kyverna is also advancing miv-cel in generalized myasthenia gravis and other autoimmune disorders.
Future catalysts
Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.
Recent news
- 01
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Source: Kyverna Therapeutics
- 02
- 03
- 04
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Source: Kyverna Therapeutics
- 05
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Source: Kyverna Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kyverna Therapeutics (KYTX)?
Kyverna Therapeutics (KYTX) most recently closed at 7.75 USD, a +1.44% move versus the previous session.
What is the market cap of Kyverna Therapeutics (KYTX)?
Kyverna Therapeutics currently has a market capitalization of 480M USD on BioPharmSignal.
What does Kyverna Therapeutics do?
Autoimmune CAR T Company Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases. Miv-cel Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration. Stiff Person Syndrome The pivotal KYSA-8 study supports the first...
On which exchange is KYTX stock listed?
Kyverna Therapeutics (KYTX) is associated with NASDAQ, United States, Biopharma.
What is KYSA-8?
Stiff Person Syndrome The pivotal KYSA-8 study supports the first planned BLA for an autoimmune CAR T therapy in stiff person syndrome.
Which conditions is Kyverna Therapeutics targeting with KYSA-8?
Autoimmune CAR T Company Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases. Miv-cel Mivocabtagene autoleucel, or miv-cel, is a fully human CAR T therapy designed to produce deep B-cell depletion after a single administration. Stiff Person Syndrome The pivotal KYSA-8 study supports the first...
How does Kyverna Therapeutics describe recent progress with KYSA-8?
Completion of the rolling miv-cel BLA submission in stiff person syndrome is expected in the fourth quarter of 2026.
What is Autoimmune?
Autoimmune CAR T Company Kyverna Therapeutics develops autologous CD19-directed CAR T-cell therapy for B-cell-driven autoimmune diseases.